This phase I trial is evaluating the safety of a new antibody-targeting therapy (TG-1801) in patients with B-Cell Lymphoma.
This trial is treating patients with B-Cell Lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 First-in-Human Study of Bispecific Antibody TG-1801 in Subjects With B-Cell Lymphoma
TG Therapeutics, Inc.
This is an open-label, multi-center, accelerated titration design study. Participants will receive TG-1801 as an intravenous infusion over 1-hour, in 4-week (28 day) cycles.
Recruiting Hospitals Read More